Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
NCT07322718
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
27
Enrollment
OTHER
Sponsor class
Conditions
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Interventions
BIOLOGICAL:
RXIM002 product
Sponsor
Ruijin Hospital
Collaborators
[object Object]